With increased market expectations and new, more stringent regulatory hurdles, for many, establishing a partnership with the right contract development and manufacturing organization (CDMO) is more cost effective than investing internally in their own infrastructure. Selecting the \u201cright\u201d outsourcing partner is a strategic priority for pharmaceutical and biotech companies seeking to get their product to market as quickly as possible. It is important to take the time to carefully vet each CDMO under consideration for your project, as described above, in order to find the CDMO partner with the right scientific expertise and industry experience to keep your project on track and ensure timely market entry.<\/p>\n
In this whitepaper learn more about what to consider when outsourcing an injectable project to a CDMO like Simtra BioPharma Solutions.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":""},"class_list":["post-2273","resource","type-resource","status-publish","hentry"],"acf":[],"yoast_head":"\n